LipoCol Forte capsules reduce the risk of liver cancer: A propensity score-matched, nationwide, population-based cohort study

Table 3 Incidence and hazard ratios of liver cancer, stratified by the duration of LipoCol Forte capsules use

Variable	n	PY	IR	cHR	95%CI	P value	aHR1	95%CI	P value
Non-use of LipoCol Forte capsules as reference	3848	186604	20.621	1.00	Reference		1.00	Reference
LipoCol Forte capsules
< 28 d	3115	161794	19.253	0.9	(0.86, 0.94)c	< 0.001	0.94	(0.89, 0.98)b	0.006
28-84 d	533	27871	19.124	0.87	(0.79, 0.95)b	0.002	0.79	(0.72, 0.87)c	< 0.001
> 84 d	52	2457	21.165	0.99	(0.75, 1.3)	0.925	0.64	(0.48, 0.84)b	0.001

¹Adjusted in multivariate analysis by sex, age, comorbidities and medications.

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

PY: Person-years; IR: Incidence rate per 1000 person-years; cHR: Crude hazard ratio; aHR: Adjusted hazard ratio.